DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like HST, EAT, DVA and PPC that are seeing price strength have a high chance of carrying the momentum forward.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
by Zacks Equity Research
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Investors Should Buy Phibro (PAHC) Stock Now
by Zacks Equity Research
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery
by Zacks Equity Research
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
Here's Why You Should Retain HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
Cencora (COR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
Waters (WAT) Boosts PFAS Testing Solutions With New Cartridges
by Zacks Equity Research
Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.
High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio
by Zacks Equity Research
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail
by Zacks Equity Research
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
PetIQ (PETQ) Broadens Minties Line With Large Dogs Dental Treats
by Zacks Equity Research
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
Here's Why You Should Buy Insulet (PODD) Stock Right Now
by Zacks Equity Research
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
by Zacks Equity Research
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.